Test your knowledge on BCMA targets

BCMA is a new target in which of the following hematologic malignancies?
B-cell lymphoma
Multiple myeloma
Acute lymphoblastic leukemia
Large B-cell lymphoma
Belantamab mafodotin is BCMA-directed CAR T-cell therapy
True
False
Ciltacabtagene autoleucel and idecabtagene vicleucel both have REMS programs.
True
False
What is the current indication for BCMA-directed CAR T-cell therapies in relapsed/refractory multiple myeloma?
At least 4 lines of prior therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
3 or more lines of prior therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
At least 5 lines of prior therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
None of the above
0
{"name":"Test your knowledge on BCMA targets", "url":"https://www.poll-maker.com/QLM2XZSQC","txt":"BCMA is a new target in which of the following hematologic malignancies?, Belantamab mafodotin is BCMA-directed CAR T-cell therapy, Ciltacabtagene autoleucel and idecabtagene vicleucel both have REMS programs.","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker | Super Surveys